Eleven months after breaking ground, biopharmaceutical company BeiGene celebrated a milestone for its $700 million manufacturing and R&D facility in Hopewell. On March 21, the last piece of structural ...

BeiGene ONC is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating that BeiGene ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today reinforced ...

The stock price of BeiGene (NASDAQ: BGNE), a China-based biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a fall of 15% over the last ...

“This site is going to help us develop and bring medicines to millions and millions more patients,” BeiGene co-founder, Chairman and CEO John Oyler enthused during the global oncology company’s recent ...

A week ago, BeiGene, Ltd. (NASDAQ:BGNE) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. The results overall were credible, with revenues of ...

With an FDA target decision date set for next week, BeiGene and Novartis’ tislelizumab has a real chance of becoming the first China-developed PD-1 cancer immunotherapy to reach the U.S.—about eight ...

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal ...

BeiGene Ltd showcases robust revenue growth and a significant reduction in net loss, reflecting strong commercial capabilities. Internally developed drugs and strategic collaborations position BeiGene ...

SUZHOU, CHINA - NOVEMBER 22: The cGMP biopharmaceutical manufacturing facility of BeiGene Co. Ltd, a clinical-stage biopharmaceutical company based in Beijing and focused on developing ...

LOS ANGELES (Reuters) - Amgen Inc <AMGN.O> said on Thursday it will take a 20.5% stake in BeiGene Ltd <6160.HK> in a deal to expand the California-based biotechnology company's presence in China, the ...

BeiGene Ltd (NASDAQ:BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks. AbbVie’s (NYSE:ABBV) patent case, which claims ...